Vitamin D and Multiple Myeloma: A Scoping Review

Curr Oncol. 2023 Mar 11;30(3):3263-3276. doi: 10.3390/curroncol30030248.

Abstract

As the global incidence of multiple myeloma (MM) increases, the identification of modifiable risk factors for disease prevention becomes paramount. Maintaining optimal vitamin D status is a candidate for prevention efforts, based on pre-clinical evidence of a possible role in disease activity and progression. A structured scoping review was performed to identify and describe human-level research regarding the association between vitamin D and MM risk and/or prognosis. Searches of three databases (OVID-Medline, OVID-Embase, and OVID-Cochrane Library) yielded 15 included publications. Vitamin D deficiency is fairly common among patients with MM, with 42.3% of participants in the studies identified as having a vitamin D deficiency. No included publication reported on vitamin D status and the risk of developing or being newly diagnosed with MM. Possible associations with vitamin D that warrant future exploration include the incident staging of MM disease, the occurrence of peripheral neuropathy, and survival/prognosis. Vitamin D receptor (VDR) polymorphisms associated with MM also warrant further investigation. Overall, this scoping review was effective in mapping the research regarding vitamin D and MM and may help support new hypotheses to better describe this association and to better address identified knowledge gaps in the literature.

Keywords: hematology; multiple myeloma; oncology; scoping review; vitamin D.

Publication types

  • Review

MeSH terms

  • Humans
  • Multiple Myeloma* / drug therapy
  • Prognosis
  • Risk Factors
  • Vitamin D / therapeutic use
  • Vitamin D Deficiency* / drug therapy
  • Vitamin D Deficiency* / epidemiology

Substances

  • Vitamin D

Grants and funding

This research received no external funding.